Supplementary Table 2. Trastuzumab efficacy for triple-positive breast cancer in CMC data according to the stage

Stage	RFS*	p-value
I	Log-rank (Mantel-Cox)	Not assessed
II	Log-rank (Mantel-Cox)	0.738
III	Log-rank (Mantel-Cox)	0.356

CMC=Seoul St. Mary's Hospital of the Catholic Medical Center; RFS= recurrence-free survival.
*Kaplan-Meier survival analysis of RFS.